UPDATE: Novo Nordisk Says ‍Trial Met Primary End-Point by Demonstrating Non-Inferiority in Rate of Severe or Blood Glucose Confirmed Symptomatic Hypoglycemia of Tresiba vs Insulin Glargine
Charles Gross